#board

Board of directors

CB_Headshot_Anker_Lundemose_Small-1

Anker Lundemose, MD PhD

Chair

CEO at Mission Therapeutics focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need.

CB_Headshot_Roderick_Verhelst_Small-1

Roderick Verhelst, PhD

Bioqube Ventures

Principal at Bioqube Ventures focusing on sourcing, financing and developing innovative therapeutic assets and technologies.

CB_Headshot_Jeroen_Bakker_Small-1

Jeroen Bakker, PhD

Novo Seeds

Principal at Novo Holdings and part of the Novo Seeds team focusing early-stage financing and development of strong and competitive companies.

CB_Headshot_Nick_Laursen_Small-1

Nick Stub Laursen, PhD

Head of Discovery & Co-founder

Nick has extensive experience in antibody characterization and has worked within the field of complement research for more than 15 years.

CB_Headshot_Mikkel_Pedersen_Small_003

Mikkel Wandahl Pedersen, PhD

CEO & CSO

Seasoned R&D executive and scientific leader with over two decades of experience in antibody development from immuno-oncology and autoimmune disease drug discovery programs.

CB_Headshots_Eva_Van_Overmeire_Small_003

Eva Van Overmeire, PhD

Senior Investment Manager

Senior Investment Manager at Korys focusing on investments in companies developing science-based solutions that prevent or treat diseases.

CB_Headshot_Janine_Small

Janine Schuurman, PhD

Antibody enthusiast and molecular Immunologist

Formerly served as SVP Antibody Research and Technology at Genmab. Pioneered IgG4 biology and IgG1-complement interactions leading to groundbreaking insights in antibody biology. Co-inventor of numerous therapeutic antibodies, including FDA-approved RYBREVANT® (amivantamab) and EPKINLY® (epcoritamab). Also co-inventor of the bispecific antibody platform DuoBody® and effector function-enhanced HexaBody® and HexElect® technologies.

#advisors

Advisors

CB_Headshot_Brian_Small

Brian Kotzin, MD

Rheumatologist and Immunologist

Brian recently served as SVP and CMO at Nektar Therapeutics. Previous Head of the Inflammation Therapeutic Area and Vice President, Head of Medical Sciences at Amgen. Trained rheumatologist and immunologist and previously Professor of Medicine at the University of Colorado.

CB_Headshot_Frank_Small

Frank Landolt, PhD

Patent attorney and transactional lawyer

Previously member of the management team at Ablynx, responsible for IP strategy, building a strong patent estate and involved in negotiating various partnerships with leading pharma companies. Ablynx was acquired by Sanofi in 2018 for $4.8B.

CB_Headshot_Gregers_Andersen_Small_004

Gregers R. Andersen, PhD

Complementologist and structural biologist

Gregers has more than 25 years of experience within the complement system and structural biology and has served as an advisor for several pharmaceutical companies with complement targeting drugs in their pipeline. Gregers is currently Professor at the department of Molecular Biology and Genetics at Aarhus University where he is leading his own research group.

© 2022 Commit Biologics. All rights reserved.

CB_Brandmark_Light-Green